David M. Reese - May 5, 2024 Form 4 Insider Report for AMGEN INC (AMGN)

Role: EVP & Chief Technology Officer
Signature: /s/ David M. Reese
Stock symbol: AMGN
Transactions as of: May 5, 2024
Transactions value $: -$197,047
Form type: 4
Date filed: 5/7/2024, 08:37 PM
Previous filing: May 3, 2024
Next filing: May 9, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Tax liability	-$197K	-633	-1.07%	$311.29	58.7K	May 5, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,363 RSUs which will vest on 4/30/2025; 2,611 RSUs which will vest in installments of 1,286 on 5/2/2025, and 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2	These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Content

These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,363 RSUs which will vest on 4/30/2025; 2,611 RSUs which will vest in installments of 1,286 on 5/2/2025, and 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

These shares include 449 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.